Research map: Comparative Effectiveness of Sacubitril/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study

Back to the article

Papers in this map

  1. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction · John J.V. McMurray · 2019 · 7146 citations · Cited by this paper
  2. Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly · 2025 · Related
  3. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure · John J.V. McMurray · 2014 · 6987 citations · Cited by this paper
  4. Colchicine for Cardiovascular Prevention: Clarity Amidst the Confusion · 2025 · Related
  5. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association · Seth Shay Martin · 2024 · 2663 citations · Cited by this paper
  6. Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy · 2025 · Related
  7. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines · Paul A. Heidenreich · 2022 · 2283 citations · Cited by this paper
  8. Cardiovascular Outcomes Associated with Cholinesterase Inhibitor Use in Individuals at High Cardiovascular Risk · 2025 · Related
  9. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors · Gary D. Lopaschuk · 2020 · 908 citations · Cited by this paper
  10. Redefining Cardiac Sarcoidosis with Advanced Imaging and Therapeutic Strategies · 2025 · Related
  11. Propensity Score Methods for Confounding Control in Nonexperimental Research · M. Alan Brookhart · 2013 · 611 citations · Cited by this paper
  12. One-Year Prognostic Differences and Management Strategies between ST-Elevation and Non-ST-Elevation Myocardial Infarction: Insights from the PRAISE Registry · 2025 · Related
  13. HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America · Biykem Bozkurt · 2024 · 424 citations · Cited by this paper
  14. De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making · 2026 · Related
  15. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction · Thomas M. Maddox · 2024 · 307 citations · Cited by this paper
  16. Cost-Effectiveness and Price Threshold Analysis of Tafolecimab in Chinese Patients with Elevated LDL Cholesterol Despite Statin Therapy · 2025 · Related
  17. A systematic review of validated methods for identifying heart failure using administrative data · Jane S. Saczynski · 2012 · 288 citations · Cited by this paper
  18. Disproportionality Analysis of Ivabradine in the US FDA Adverse Event Reporting System: A Real-World Study Across Overall and Indication-Specific Populations · 2025 · Related
  19. Methods to Analyze Time‐to‐Event Data: The Cox Regression Analysis · Samar Abd ElHafeez · 2021 · 197 citations · Cited by this paper
  20. Mineralocorticoid Receptor Antagonism with Finerenone: A New Era in the Management of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction · 2025 · Related
  21. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload · Milton Packer · 2021 · 173 citations · Cited by this paper
  22. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits · Alberto Preda · 2024 · 162 citations · Cited by this paper
  23. Understanding of interaction (subgroup) analysis in clinical trials · Milos Brankovic · 2019 · 131 citations · Cited by this paper
  24. Propensity Score Weighting and Trimming Strategies for Reducing Variance and Bias of Treatment Effect Estimates: A Simulation Study · Til Stürmer‎ · 2021 · 123 citations · Cited by this paper
  25. Validity of International Classification of Diseases (ICD)-10 Diagnosis Codes for Identification of Acute Heart Failure Hospitalization and Heart Failure with Reduced Versus Preserved Ejection Fraction in a National Medicare Sample · Benjamin A. Bates · 2023 · 110 citations · Cited by this paper
  26. Diagnostic accuracy of the International Classification of Diseases , Tenth Revision , codes of heart failure in an administrative database · Pauline Bosco‐Lévy · 2018 · 89 citations · Cited by this paper
  27. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review · Domingo Andrés Pascual-Figal · 2021 · 77 citations · Cited by this paper
  28. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis · Alberto Aimo · 2020 · 73 citations · Cited by this paper
  29. Risk Factors for Heart Failure in the Community: Differences by Age and Ejection Fraction · Alanna M. Chamberlain · 2019 · 72 citations · Cited by this paper
  30. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy · Jishnu Malgie · 2023 · 62 citations · Cited by this paper
  31. Molecular mechanisms of sacubitril/valsartan in cardiac remodeling · Nor Hidayah Mustafa · 2022 · 53 citations · Cited by this paper
  32. Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling · Husam M. Salah · 2022 · 52 citations · Cited by this paper
  33. SGLT2i Versus ARNI in Heart Failure with Reduced Ejection Fraction: A Systematic Review and Meta-Analysis · Yuling Yan · 2021 · 48 citations · Cited by this paper
  34. Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review) · Bixian Chen · 2024 · 41 citations · Cited by this paper
  35. Efficacy of sacubitril‐valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta‐analysis · Xingchun Mo · 2023 · 23 citations · Cited by this paper
  36. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study · Fu‐Chih Hsiao · 2021 · 17 citations · Cited by this paper
  37. Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis · Yao Neng Teo · 2021 · 17 citations · Cited by this paper
  38. Effectiveness and safety of angiotensin receptor-neprilysin inhibitor and sodium–glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction: a meta-analysis · Yun Huang · 2022 · 9 citations · Cited by this paper
  39. Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus · Ming‐Lung Tsai · 2023 · 9 citations · Cited by this paper

Source: OpenAlex (CC0)